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ABSTRACT 
Pharmacogenomics and personalized medicine promise to improve 
health care for chronically ill patients by increasing drug 
effectiveness and minimizing side effects of drug therapy. There 
may also be substantial savings realized by eliminating costs 
associated with failed treatment. Since these issues are not 
adequately explored across disease areas, the overall economic 
impact of personalized medicine remains uncertain. Using asthma 
as illustration, this paper describes a new framework for 
analyzing the potential value of using a pharmacogenomic 
diagnostic test in clinical practice. 
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Broadly considered, personalized medicine is the use of 
molecular markers to guide the diagnosis and treatment of 
disease toward the characteristics of individual patients. It 
derives from the idea that an apparently indistinct disease seen 
in a population reflects a group of distinct molecular disorders 
in individuals, generating inter-patient variability in disease 
progression and treatment response. [1-3] Individual variation 
accounts for a wide range of medical and economic consequences, 
from inefficiencies in drug discovery and development to 
ineffectiveness of drug treatment to drug-induced morbidity and 
mortality. Addressing these consequences via personalized 
medicine could benefit patients, and impact health care 
providers and payers, and the pharmaceutical industry. [4-6]  
The techniques of personalized medicine — including molecular 
diagnostics, pharmacogenomics, and targeted therapies — provide 
a direct link between pathogenic molecular mechanisms and 
clinical symptoms. When appropriate markers are known, 
diagnostic tests allow precise diagnosis and dosing, prediction 
of disease progression, prediction of treatment response and 
prediction of adverse drug reactions for individual patients. 
Pharmacogenomic markers, probably the most widely discussed 
molecular markers, would use genomic information to 
individualize disease diagnosis and treatment. Throughout this 
paper, we use the term pharmacogenomics to refer broadly to the 
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relationship between gene variation and drug effect. Though 
sometimes used interchangeably, pharmacogenetics has been most 
often used  in the research literature in connection with 
variation in drug metabolizing enzymes. (See Bailey or Evans) 
Pharmacogenomics promises safer and more effective drug 
treatment, biomarkers to guide drug discovery at its earliest 
stages, and a context for prioritizing future advances in 
medical treatment on the basis of the relative safety, efficacy, 
or dosing regimens of existing and potential therapies. [7-10] 
There may also be substantial savings realized by eliminating 
costs associated with failed treatment. But pharmacogenomics 
presents many challenges to our health care, drug development, 
medical education, regulatory, and social systems. [11] The 
potential costs are also numerous — more expensive drugs, 
threats to patient insurability, reduced drug revenue, increased 
regulatory complexity, reduced physician independence, and 
threats to personal privacy. Since these issues are not 
adequately explored across disease areas, the overall economic 
impact of personalized medicine remains uncertain. 
Economic analyses of pharmacogenomics have focused on cost 
effectiveness and cost benefit. Typically the data for these 
kinds of analyses in health care come from population-based 
studies, such as randomized controlled trials or cohort studies. 
[12] But for most indications, a pharmacogenomic intervention 
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has not yet been developed, so a population-based study 
comparing interventions is impossible. University of Washington 
researchers developed a set of cost-effectiveness criteria for 
considering specific disease, drug, and genetic test 
combinations. [13] A cost impact analysis from ATKearney 
predicted that total revenues for current blockbuster drugs in 
the cholesterol-lowering and arthritis markets would decline, 
that pharmacogenomics would reduce potential revenues for drugs 
that show only reduced side effects but no improved efficacy 
over existing technology, and that, depending on the indication, 
overall market size could increase using pharmacogenomics to 
address currently unmet medical needs. [14]  
Currently absent in the debate emerging around 
pharmacogenomics is a framework for evaluating its benefits that 
is robust and sensitive to all its potential advantages. A 
modified cost offset analysis could demonstrate whether 
pharmacogenomics would prove worthwhile in economic terms. A 
cost offset is recognized if greater utilization of one aspect 
of health care, say pharmaceuticals, reduces the use of other 
types of health care. Although cost offset studies are rarely 
able to take account explicitly for treatment response, in the 
United States they have proven of interest to payers to make 
decisions about coverage. [15, 16] Were it possible through a 
diagnostic test to identify who would not respond to a given 
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therapy, the costs of non-response could be eliminated for many 
patients and reduced for the population as a whole—thereby 
generating a cost-offset relative to treatment costs in the 
absence of such a test. Key variables determining this potential 
cost offset are the sensitivity of the test, cost of the test, 
effectiveness of personalized treatments, and the relative costs 
of responders and non-responders. 
This paper presents an analytical framework for considering 
many of the tradeoffs that may arise when a diagnostic test is 
used to predict drug response. We offer an empirical test of 
these ideas, using patients with asthma to illustrate the 
framework. These results could potentially guide future economic 
evaluation of new diagnostic tests based on advances in 
pharmacogenomics. Importantly, they may also influence biomarker 
discovery strategies to ensure consistency between market 
priorities and the future stream of product introductions. 
 
DATA and METHODS 
We used retrospective claims data to define our study 
population and calculate total health care costs on a per-
patient annualized basis. Our data were derived from the 
MarketScan claims and encounter databases for 1995–2000. 
MarketScan is the largest set of databases of its kind, 
containing detailed descriptions of inpatient and outpatient 
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medical care services for persons who are covered in over 160 
large corporate-sponsored healthcare plans (approximately 2.8 
million covered lives in 2000). The analytic file contains 
patients with fee-for-service health plans and those with 
partially- or fully-capitated plans. Because data on costs were 
not available for the capitated plans, the value of patients’ 
service utilization under the capitated plan was priced and 
imputed using average payments per procedure, from the 
MarketScan FFS inpatient and outpatient claims, further 
stratified by region and year.  
Our framework determines the economic consequences of 
implementing pharmacogenomics in the clinic using a diagnostic 
test to predict drug response. Using retrospective claims data 
for asthma patients, we calculated the cost offset realized by 
predicting the likelihood of response to an alternative existing 
treatment using a hypothetical pharmacogenomic test. Because the 
diagnostic test is hypothetical, the alternative treatment 
remains undefined. This illustrates that our framework is 
general and could be applied to other indications where 
diagnostic tests for personalizing treatment regimens have not 
been developed.   
We employed “risk analysis” as our analytic approach to 
compare the health care costs of an observed treatment protocol 
(Base Case) with those in a hypothetical treatment protocol 
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including a pharmacogenomic test for drug efficacy (Test Case). 
The difference between the overall costs of the Base Case, where 
non-responding patients continue to suffer their symptoms 
despite treatment, and the Test Case, where a pharmacogenomics 
test helps identify an appropriate treatment, is the cost offset 
realized as a result of using the test.  
Individuals between the ages of 4 and 64 with evidence of 
asthma were selected from the intersection of the claims, 
encounter, enrollment, and pharmaceutical data files. We defined 
evidence of asthma as follows:   
• At least two outpatient claims with primary or secondary 
diagnoses of asthma; or At least one emergency room claim 
with primary diagnosis of asthma, and a drug transaction 
for an asthma drug 90 days prior or 7 days following 
emergency room claim; or At least one inpatient claim with 
primary diagnosis of asthma; or 
• A secondary diagnosis of asthma and a primary diagnosis of 
respiratory infection in the same claim. 
We included only patients with evidence of outpatient 
prescription drug coverage and evidence of continuous plan 
enrollment during the pre-study (12 months) and follow-up 
periods (24 months), a total of 36 months. We followed subjects’ 
resource utilization for twenty-four months after their index 
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date (the date on which these inclusion criteria are met). We 
excluded patients with a diagnosis of chronic obstructive 
pulmonary disease (COPD), or with one or more diagnosis or 
procedure codes indicating pregnancy or delivery.  
In our analysis, total health care costs are actual 
payments to providers for all health services, including 
inpatient hospitalizations, outpatient services and filled 
prescriptions, whether or not directly related to asthma. Thus, 
our results are relatively insensitive to diagnostic coding 
mistakes or discrepancies. 
The population of Base Case patients was subdivided into 
responders and non-responders using a binary measure of 
medication complexity as a proxy for whether the asthmatic 
responded to treatment over the study period. Asthmatics with a 
high level of medical complexity were designated Non-responders 
and were defined as patients with at least three different 
pharmaceutical prescriptions or with at least one asthma 
emergency room (ER) visit or hospitalization over the first 12 
months of the study period. All other asthmatics were 
categorized as Responders, or asthmatics with a low level of 
medical complexity. 
We simulated total healthcare costs under a variety of 
conditions, including test cost, test sensitivity, and the 
probability of treatment response. We randomly selected patients 
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without replacement based on the probability of response to 
treatment parameter (hereafter called “Sample A”). We used a 
“seed value” to retain the same randomly selected patients 
across iterations of the simulation. Based on the test 
sensitivity parameter, we randomly selected Non-responders from 
Sample A who would become Responders (hereafter called “Sample 
B”). Then to estimate the cost of being a Responder for each of 
the selected Non-responders, we randomly selected a Responder 
patient from the Base Case and assigned that patient’s cost to 
the patient in Sample B. The cost of the test was added to the 
total healthcare costs for all non-responders in Sample A. We 
then compared these simulated costs (hereafter called “Test 
Case” costs) to the Base Case costs. Seven hundred variants of 
the simulation were run, examining 10 values of test 
sensitivity, 14 values of test cost, and 5 values of probability 
of treatment response (i.e., 700=10x14x5). 
The range of test costs we modeled was derived from data 
provided by  the Molecular Diagnostic Testing Unit at a major 
teaching hospital in Boston. The reported costs, which 
represented a range of charges for genetic tests that are 
currently used in the hospital, across all disease categories, 
varied from $135 to $1850. In the simulation, we extended the 
range to $100 to $2100 to account for possible economies of 
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scale and the potential for more costly technological advances 
in the future. 
The test sensitivity parameter determined the probability that 
Non-responders from the Base Case would become Responders in the 
Test Case. In our simulation, we iterated the value of this 
parameter from 0.1 to 1.0 in 0.1 increments to determine a model 
for the effect of this parameter on treatment costs using the 
test. Test specificity was not modeled in our algorithm since it 
does not impact the transition of Non-responders to Responders, 
and thus, under our hypothesis, it would not affect the 
difference in overall health care costs. 
The probability of treatment response parameter determined the 
distribution of Responders and Non-responders in each simulation 
and was iterated in 0.10 increments beginning with the special 
case of the observed value of 0.667. We reasoned that the 
probability of treatment response could be higher than the 
response rate determined by the medical complexity analysis. 
We compared the Base Case and Test Case costs, and used T-
tests to evaluate the significance of the differences.  
 
Results 
 
We identified 28,324 asthmatics in the sample. The mean costs 
for all asthmatics over the study period were $3,805. Using 
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medical complexity, we classified 66.7% as Responders and 33.3% 
as Non-responders, giving the observed 0.667 probability of 
treatment response. As expected, Non-responders had higher 
health care costs than Responders, with annualized mean costs of 
$5,132 and $3,140 per patient, respectively. The typical 
Responder in our sample experienced a 0.6% chance of an asthma-
related emergency room visit, and a 0.4% chance of an asthma-
related hospitalization during the 24-month study period. On the 
other hand, the typical Non-responder in our sample had an 8.7% 
chance of visiting the ER for asthma, and a 5.8% chance of being 
hospitalized for asthma, during the same period.  These 
estimates are consistent with those from other recent studies of 
asthma costs using patient claims data. For example, Birnbaum et 
al. found that annual per-capita employer expenditures for 
asthmatic patients were 2.5 times higher than patients without 
asthma claims ($5,385 versus $2,121, respectively). [17]  
Exhibit One shows the simulated mean cost savings for varying 
levels of test sensitivity, test cost, and treatment 
effectiveness. These selected results characterize the cost 
differential (Base Case – Test Case) and how it varies with test 
sensitivity and test cost and probability of treatment response. 
With low test costs, low diagnostic test sensitivity between 
0.3-0.4 yielded positive cost savings. For diagnostic tests 
costing more than $1,050, however, no cost-savings occur 
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regardless of the sensitivity of the test, or the effectiveness 
of the treatment. For all probabilities of treatment response 
examined, the cost savings increases with decreasing test cost 
and increasing test sensitivity. 
Under the most favorable circumstances, with a test 
sensitivity of 100 percent and $100 test cost, using the 
pharmacogenomic test could result in cost savings of $410 per 
person per year even if use of the test did not result in any 
additional gain in treatment effectiveness. It seems likely, 
however, that the use of a pharmacogenomic test would also 
result in some additional gains in treatment effectiveness, even 
in the absence of new therapies, by directing patients to 
treatments to which they would be more likely to respond. The 
cost savings associated with incremental improvements in the 
effectiveness of therapies, when coupled with a diagnostic test, 
are also shown in Exhibit 1. It is apparent that the sensitivity 
of the diagnostic test influences the magnitude of potential 
cost savings more than improvements in the effectiveness of 
treatments. However, potential cost savings are also sensitive 
to the cost of the test. 
 
 
Discussion 
 
  14 
More than 30 years ago, Lewis Thomas, in his collection of 
“Notes of a Biology Watcher” from the New England Journal of 
Medicine, insightfully described the differences between what he 
called, “halfway technology” and the “genuine technology of 
medicine.” He noted that new therapies based on a solid 
understanding of the underlying scientific mechanisms would make 
clinical decisions about treatment much easier. Thomas may well 
have correctly predicted that the “genuine technology of 
medicine” would come when new therapies would be based on a full 
understanding of scientific mechanism. He may not have realized 
how many new and different kinds of questions would be raised, 
as a result of the changes in the way treatment selection 
decisions and future R&D investment decisions are made. 
Nevertheless, he was writing — at least in part — about 
pharmacogenomics. 
We found that personalizing therapy through the use of a 
diagnostic test would result in a cost offset from the 
perspective of payers when the test is sensitive and the cost of 
performing the test is relatively modest. From a societal 
perspective, the benefits of personalized medicine are 
potentially much greater than those demonstrated in this paper. 
This underestimate of benefits results largely because the 
analysis of medical costs does not include the indirect benefits 
that accrue to payers, employers and society when patients make 
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more rapid recovery from illness and resume productive lives. 
For example, Weiss et al. estimated that direct medical costs 
comprise approximately 58 percent of the estimated societal 
costs, with costs resulting from productivity loss accounting 
for the remaining portion. [18] Other societal costs include 
those associated with absences from school, quality of life, and 
caregiver burden [19-22]. 
The economic benefits that accrue from personalized medicine 
would be realized as cost offsets from avoided costs of 
treatment non-response, including unnecessary medication costs 
and potential adverse reaction treatment costs. In addition to 
prioritizing the economic viability of diagnostics aimed at 
multiple personalized medicine approaches such as dosing, side 
effects, or treatment response, the analytical framework 
developed here has the potential to guide the target profile of 
future drug discovery efforts. 
Further Considerations The availability of a test for drug 
responders adds a layer of complexity to a set of similar 
decisions that are already commonplace. A key policy question 
will be whether the costs of treatment failure could be offset 
by the costs of diagnostic testing when a new diagnostic becomes 
available. 
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We now extend the results described above by offering a set of 
illustrative calculations to examine the tradeoffs between 
diagnostic testing costs and costs arising from the failure of 
the initial therapy selection. We analyze the following 
situation: Current practices for many diseases, including 
asthma, call for patients to be initially treated with a first 
line therapy. If they fail to respond, alternative therapies are 
selected until a suitable one is identified. Suppose there is a 
diagnostic test that can report the likely response of a given 
patient to alternative existing therapies. In reality, there may 
be a number of possible therapies from which to choose, and it 
would actually require layers of testing to narrow the field to 
the ideal drug. For simplicity, we are considering only one 
therapeutic alternative and one diagnostic test with 90% 
sensitivity and 100% specificity for 1000 patients. 
Exhibit 2 presents the results of these calculations. Choosing 
to administer the diagnostic test to newly diagnosed patients at 
the outset incurs the cost of testing a large population but 
avoids the cost of non-response to the initial therapy. Testing 
only patients not responding to the initial therapy after six 
months would reduce testing costs by limiting the size of the 
population tested, but would incur greater costs of therapy as a 
result of treatment failures. 
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Columns C and D of table 2 present the three-year cumulative 
(without discounting) costs or cost savings associated with the 
two alternative strategies — test all early or test a sub-
population later? Results of the calculations suggest that, when 
considering alternate existing therapies of comparable expense, 
testing all patients early on makes the most sense unless the 
test is costly or not sensitive.  
A dimension of personalized medicine not directly considered 
in this paper is the pairing of diagnostic testing with novel 
treatments targeted specifically to individuals whom the tests 
identify as appropriate candidates. Novel treatments such as 
biologics, treatments based on recombinant DNA, etc., are 
increasingly providing treatment options for patients who are 
unresponsive to conventional therapies, or who have conditions 
for which no treatment previously existed. Often, however, such 
novel treatments are very expensive. The results in Exhibit 2 
show that testing could even be valuable if the novel 
therapeutic is significantly more expensive. 
Limitations of Analysis Our analysis is subject to the 
limitations associated with the use of a retrospective, 
administrative database to infer episodes of illness and medical 
care. In particular, with respect to medications, we are able to 
determine that prescriptions were filled, but not whether the 
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patients actually complied with the regimen. This limitation may 
be particularly important in the asthma context, in which some 
of the medications are likely to be prescribed for use on an “as 
needed” basis. 
Policy Implications Sooner, rather than later, new drugs will 
begin to emerge as a result of the application of 
pharmacogenomics and other advances in biological sciences. Our 
increased understanding of the molecular basis of disease will 
likely yield efficiencies that will ultimately improve the 
quality of care and lower health-related costs.  However, in the 
process of integrating this new knowledge and its related 
technologies, there will be substantial value migration in 
health care that will require new models to assess value and 
evaluate the true contribution to patient care.  
Some of these drugs will prove to be highly effective, or much 
better tolerated than their predecessors, among certain members 
of a candidate pool that meet criteria that are identifiable 
with the help of a molecular marker. A diagnostic test, based on 
such a marker, will identify the patients who are the promising 
candidates.  A portion of those who would benefit from the new 
drug may also be successfully managed with existing, less costly 
treatments. This paradigm suggests the need to carefully 
consider alternative clinical policies that assess the 
appropriate timing and evaluate the cost effectiveness of the 
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diagnostic test. Additionally, as scientific advances promise to 
bring extraordinary changes to the practice of medicine, it will 
be critical to ensure that commercial, scientific, technological 
and clinical incentives be aligned in order to facilitate the 
stream of innovative new therapies that we anticipate will 
emerge from medical research, and to maintain reliable access 
for physicians and for their patients. Our approach provides a 
new tool for these considerations. Our results suggest that 
diagnostic tests in the context of personalized medicine would 
be valuable in a wide range of circumstances.  
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Exhibit 1 
 Selected simulation results, illustrating the value of pharmacogenomic 
testing in asthma treatment 
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**Based on N=9,444 non-responding asthmatics  
 
 
Test Cost 
Probability 
of Treatment 
Response 
Annualized Cost Savings ($)* 
Per Person at Various Levels of 
Test Sensitivity 
  Test Sensitivity 
  $100  1.0 0.9 0.5 0.1 
 0.667 
(observed) 410 358 192 6 
 0.70 452 393 198 2 
 0.80 483 468 254 21 
 0.90 588 515 283 48 
 1.0 635 588 320 36 
$350      
 0.667 
(observed) 326 275 109 -77 
 0.70 369 310 115 -81 
 0.80 399 384 171 -62 
 0.90 505 431 200 -35 
 1.0 551 505 237 -48 
 $700      
 0.667 
(observed) 210 158 -8 -194 
 0.70 252 193 -2 -197 
 0.80 283 268 54 -179 
 0.90 388 315 83 -152 
 1.0 435 388 120 -164 
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Exhibit 2 
Cost savings (in parentheses) or burdens of using a 
pharmacogenomic test for drug efficacy in 1000 patients. In 
Scenario 1, patients not responding to the first-line treatment 
after six months are tested to determine the drug they are most 
likely to respond to. In Scenario 2, all patients are tested. 
 
Test 
Cost 
Prob. Of 
Treatment 
Response 
Annualized 
Cost 
Offset 
(from 
Exhibit 1) 
A.  
Scenario 1 – 
1 year out 
B. Scenario 2 
– 1 year out 
C. Scenario 1 
– 3 years out 
without 
discount 
D. Scenario 2 
– 3 years out 
without 
discount 
$100 0.7 $393 ($12,516.67) $8300.00 ($104,216.67) ($175,100.00) 
0.9 $515 ($43,916.67) ($54,500.00) ($198,416.67) ($363,500.00) 
$350 0.7 $393 $70, 816.67 $258,300.00 ($20,883.33) $74,900.00 
0.9 $515 $39,416.67 $195,500.00 ($115,083.33) ($113,500.00) 
$700 0.7 $393 $187,483.33 $608,300.00 $95,783.33 $424,900.00 
0.9 $515 $135,333.33 $504,000.00 ($60,666.67) $112,000.00 
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